1h Free Analyst Time
Myc Proto Oncogene Protein (Transcription Factor p64 or Class E Basic Helix Loop Helix Protein 39 or MYC) - Myc (c-Myc) protein encoded by Myc gene, a regulator gene that code for a transcription factor. The protein plays a role in cell cycle progression, apoptosis and cellular transformation. Myc protein is a transcription factor that activates expression of many genes through binding enhancer box sequences and recruiting histone acetyltransferases. It also acts as a transcriptional repressor. By binding Miz-1 transcription factor and displacing the p300 co-activator, it inhibits expression of Miz-1 target genes. In addition, myc has a direct role in the control of DNA replication. Myc is a proto-oncogene and it often upregulates in many types of cancers. Myc over expression stimulates gene amplification presumably through DNA over-replication. Speak directly to the analyst to clarify any post sales queries you may have.
Myc Proto Oncogene Protein (Transcription Factor p64 or Class E Basic Helix Loop Helix Protein 39 or MYC) pipeline Target constitutes close to 31 molecules. Out of which approximately 26 molecules are developed by companies and remaining by the universities/institutes. The molecules developed by companies in Phase II, IND/CTA Filed, Preclinical and Discovery stages are 1, 1, 12 and 12 respectively. Similarly, the universities portfolio in Preclinical and Discovery stages comprises 3 and 2 molecules, respectively. Report covers products from therapy areas Oncology which include indications Unspecified Cancer, Solid Tumor, Hematological Tumor, Lymphoma, Breast Cancer, Burkitt Lymphoma, Glioblastoma Multiforme (GBM), Hepatocellular Carcinoma, Multiple Myeloma (Kahler Disease), Non-Small Cell Lung Cancer, Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia), B-Cell Acute Lymphocytic Leukemia (B-Cell Acute Lymphoblastic Leukaemia), Blood Cancer, Colon Cancer, Colorectal Cancer, Diffuse Large B-Cell Lymphoma, Leukemia, Lung Cancer, Medulloblastoma, Metastatic Brain Tumor, Neuroblastoma, Pancreatic Cancer, Pancreatic Ductal Adenocarcinoma, Retinoblastoma, Small-Cell Lung Cancer, T-Cell Acute Lymphocytic Leukemia (T-Cell Acute Lymphoblastic Leukaemia) and Triple-Negative Breast Cancer (TNBC).
The latest report Myc Proto Oncogene Protein - Drugs In Development, 2022, outlays comprehensive information on the Myc Proto Oncogene Protein (Transcription Factor p64 or Class E Basic Helix Loop Helix Protein 39 or MYC) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews key players involved in Myc Proto Oncogene Protein (Transcription Factor p64 or Class E Basic Helix Loop Helix Protein 39 or MYC) targeted therapeutics development with respective active and dormant or discontinued projects.
The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
- The report provides a snapshot of the global therapeutic landscape for Myc Proto Oncogene Protein (Transcription Factor p64 or Class E Basic Helix Loop Helix Protein 39 or MYC)
- The report reviews Myc Proto Oncogene Protein (Transcription Factor p64 or Class E Basic Helix Loop Helix Protein 39 or MYC) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Myc Proto Oncogene Protein (Transcription Factor p64 or Class E Basic Helix Loop Helix Protein 39 or MYC) targeted therapeutics and enlists all their major and minor projects
- The report assesses Myc Proto Oncogene Protein (Transcription Factor p64 or Class E Basic Helix Loop Helix Protein 39 or MYC) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Myc Proto Oncogene Protein (Transcription Factor p64 or Class E Basic Helix Loop Helix Protein 39 or MYC) targeted therapeutics
Reasons to Buy
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for Myc Proto Oncogene Protein (Transcription Factor p64 or Class E Basic Helix Loop Helix Protein 39 or MYC)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Myc Proto Oncogene Protein (Transcription Factor p64 or Class E Basic Helix Loop Helix Protein 39 or MYC) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Table of Contents
- Introduction
- REPORT COVERAGE
- Myc Proto Oncogene Protein (Transcription Factor p64 or Class E Basic Helix Loop Helix Protein 39 or MYC) - Overview
- Myc Proto Oncogene Protein (Transcription Factor p64 or Class E Basic Helix Loop Helix Protein 39 or MYC) - Therapeutics Development
- Products under Development by Stage of Development
- Products under Development by Therapy Area
- Products under Development by Indication
- Products under Development by Companies
- Products under Development by Universities/Institutes
- Myc Proto Oncogene Protein (Transcription Factor p64 or Class E Basic Helix Loop Helix Protein 39 or MYC) - Therapeutics Assessment
- Assessment by Mechanism of Action
- Assessment by Route of Administration
- Assessment by Molecule Type
- Myc Proto Oncogene Protein (Transcription Factor p64 or Class E Basic Helix Loop Helix Protein 39 or MYC) - Companies Involved in Therapeutics Development
- Anima Biotech Inc
- Arrakis Therapeutics Inc
- Arvinas Inc
- Biogenera SpA
- Ceptur Therapeutics Inc
- Cothera Bioscience Pty Ltd
- Erasca Inc
- Escend Pharmaceuticals Inc
- Gibson Oncology LLC
- Kintor Pharmaceutical Ltd
- Kronos Bio Inc
- MecRx Pty Ltd
- Omega Therapeutics Inc
- OncoViRx LLC
- Origenis GmbH
- Peptomyc SL
- PYC Therapeutics Ltd
- Recursion Pharmaceuticals Inc
- Sapience Therapeutics Inc
- SyntheX Inc
- Myc Proto Oncogene Protein (Transcription Factor p64 or Class E Basic Helix Loop Helix Protein 39 or MYC) - Drug Profiles
- Amy-22 - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- BGA-003 - Drug Profile
- Product Description
- Mechanism Of Action
- Drugs to Inhibit MYC for Breast Cancer - Drug Profile
- Product Description
- Mechanism Of Action
- ERAS-11 - Drug Profile
- Product Description
- Mechanism Of Action
- ES-4000 - Drug Profile
- Product Description
- Mechanism Of Action
- GT-19077 - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- GT-19630 - Drug Profile
- Product Description
- Mechanism Of Action
- Myc - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- MYC - Drug Profile
- Product Description
- Mechanism Of Action
- MYC (Oncology) - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- NOV-1701 - Drug Profile
- Product Description
- Mechanism Of Action
- Oligonucleotides to Inhibit MYC for Hepatocellular Carcinoma and Non Small Cell Lung Cancer - Drug Profile
- Product Description
- Mechanism Of Action
- OMO-101 - Drug Profile
- Product Description
- Mechanism Of Action
- OMO-103 - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- OTX-2002 - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- PC-002p - Drug Profile
- Product Description
- Mechanism Of Action
- REC-0162977 - Drug Profile
- Product Description
- Mechanism Of Action
- REC-841 - Drug Profile
- Product Description
- Mechanism Of Action
- Small Molecule to Target c-Myc for Multiple Myeloma - Drug Profile
- Product Description
- Mechanism Of Action
- Small Molecules 3 to Inhibit C-Myc for Unspecified Cancer - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- Small Molecules to Inhibit c-Myc for Oncology - Drug Profile
- Product Description
- Mechanism Of Action
- Small Molecules to Inhibit C-Myc for Oncology - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- Small Molecules to Inhibit C-Myc for Unspecified Cancer - Drug Profile
- Product Description
- Mechanism Of Action
- Small Molecules to Inhibit cMYC and PTEN for Unspecified Cancers - Drug Profile
- Product Description
- Mechanism Of Action
- Small Molecules to Inhibit cMyc for Oncology - Drug Profile
- Product Description
- Mechanism Of Action
- Small Molecules to Inhibit MYC and NFKB for Lymphomas and Leukemias - Drug Profile
- Product Description
- Mechanism Of Action
- Small Molecules to Inhibit MYC and TOP1 for Oncology - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- STX-300 - Drug Profile
- Product Description
- Mechanism Of Action
- Synthetic Peptide to Inhibit C-Myc for Oncology - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- Synthetic Peptide to Inhibit cMyc for Hematological Tumor and Solid Tumor - Drug Profile
- Product Description
- Mechanism Of Action
- Target 1 (PPI Modulator) - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- Myc Proto Oncogene Protein (Transcription Factor p64 or Class E Basic Helix Loop Helix Protein 39 or MYC) - Dormant Products
- Myc Proto Oncogene Protein (Transcription Factor p64 or Class E Basic Helix Loop Helix Protein 39 or MYC) - Discontinued Products
- Myc Proto Oncogene Protein (Transcription Factor p64 or Class E Basic Helix Loop Helix Protein 39 or MYC) - Product Development Milestones
- Featured News & Press Releases
- Jun 23, 2022: Omega Therapeutics to present new preclinical data for the first epigenomic controller, OTX-2002, for hepatocellular carcinoma at the European Society of Medical Oncology's 2022 World Congress on Gastrointestinal Cancer
- Jun 15, 2022: Omega Therapeutics announces submission of Investigational New Drug application for OTX-2002, an Omega Epigenomic Controller, for MYC driven hepatocellular carcinoma
- Apr 08, 2022: Omega Therapeutics presents preclinical data on OTX-2002, first-in-class epigenomic controller, as potential treatment for hepatocellular carcinoma at the AACR Annual Meeting 2022
- Mar 08, 2022: Omega Therapeutics to present preclinical data for OTX-2002 at the American Association for Cancer Research Annual Meeting 2022
- May 06, 2021: Peptomyc SL announces treatment of first patient with its lead compound OMO-103 in a phase I/II clinical trial
- Mar 17, 2021: Omomyc, a drug developed in Vall d'Hebron, is coming to the clinical trial
- Jul 30, 2020: VHIO and home-grown spin-off Peptomyc S.L receive further funding to bring Omomyc closer to the clinic
- Jun 22, 2020: Pioneer Pharmaceuticals released the latest research results of c-Myc inhibitors at the AACR annual meeting
- Apr 01, 2019: First published demonstration of the success of Myc inhibition by Omomyc mini-protein hits Science Translational Medicine and the news
- Mar 26, 2019: Preclinical validation of new cancer inhibitor from EIT Health-supported Peptomyc
- Mar 14, 2019: A new approach to drugging a difficult cancer target
- Dec 09, 2015: Combination therapy escalates potency of Phylogica peptides against MYC-driven cancer
- Nov 16, 2015: Phylogica exceeds gold - standard for treatment of MYC - driven cancer
- Appendix
- Methodology
- Coverage
- Secondary Research
- Primary Research
- Expert Panel Validation
- Contact the Publisher
- Disclaimer
List of Tables
- Number of Products under Development by Stage of Development, 2022
- Number of Products under Development by Therapy Areas, 2022
- Number of Products under Development by Indications, 2022
- Number of Products under Development by Companies, 2022
- Products under Development by Companies, 2022
- Number of Products under Investigation by Universities/Institutes, 2022
- Products under Investigation by Universities/Institutes, 2022
- Number of Products by Stage and Mechanism of Actions, 2022
- Number of Products by Stage and Route of Administration, 2022
- Number of Products by Stage and Molecule Type, 2022
- Pipeline by Anima Biotech Inc, 2022
- Pipeline by Arrakis Therapeutics Inc, 2022
- Pipeline by Arvinas Inc, 2022
- Pipeline by Biogenera SpA, 2022
- Pipeline by Ceptur Therapeutics Inc, 2022
- Pipeline by Cothera Bioscience Pty Ltd, 2022
- Pipeline by Erasca Inc, 2022
- Pipeline by Escend Pharmaceuticals Inc, 2022
- Pipeline by Gibson Oncology LLC, 2022
- Pipeline by Kintor Pharmaceutical Ltd, 2022
- Pipeline by Kronos Bio Inc, 2022
- Pipeline by MecRx Pty Ltd, 2022
- Pipeline by Omega Therapeutics Inc, 2022
- Pipeline by OncoViRx LLC, 2022
- Pipeline by Origenis GmbH, 2022
- Pipeline by Peptomyc SL, 2022
- Pipeline by PYC Therapeutics Ltd, 2022
- Pipeline by Recursion Pharmaceuticals Inc, 2022
- Pipeline by Sapience Therapeutics Inc, 2022
- Pipeline by SyntheX Inc, 2022
- Dormant Products, 2022
- Discontinued Products, 2022
List of Figures
- Number of Products under Development by Stage of Development, 2022
- Number of Products under Development by Top 10 Indications, 2022
- Number of Products by Stage and Mechanism of Actions, 2022
- Number of Products by Routes of Administration, 2022
- Number of Products by Stage and Routes of Administration, 2022
- Number of Products by Molecule Types, 2022
- Number of Products by Stage and Molecule Types, 2022
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Anima Biotech Inc
- Arrakis Therapeutics Inc
- Arvinas Inc
- Biogenera SpA
- Ceptur Therapeutics Inc
- Cothera Bioscience Pty Ltd
- Erasca Inc
- Escend Pharmaceuticals Inc
- Gibson Oncology LLC
- Kintor Pharmaceutical Ltd
- Kronos Bio Inc
- MecRx Pty Ltd
- Omega Therapeutics Inc
- OncoViRx LLC
- Origenis GmbH
- Peptomyc SL
- PYC Therapeutics Ltd
- Recursion Pharmaceuticals Inc
- Sapience Therapeutics Inc
- SyntheX Inc
